Genomic Medicine · us
After One-Person, One-Drug Therapies Leave the Lab, Who Reviews Them—and Who Pays? The Next Hurdle for Rare-Disease Gene Therapies
The newly established Center for Therapeutic Genetics is shifting the focus from whether a drug can be made for a single patient to a more difficult institutional challenge: how to accumulate reusable safety evidence and establish review and reimbursement pathways for therapies that serve only one person or a handful of people.
Creating a gene-based drug tailored to a single child is no longer entirely unimaginable from a scientific standpoint. What is often truly difficult to replicate is the entire system surrounding the drug. With each new mutation, research teams may need to reorganize disease models, manufacturing, toxicology studies, clinical procedures, and funding sources. The nonprofit Center for Therapeutic Genetics, established by the Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory, is seeking to address precisely this recurring bottleneck of starting from scratch.
The center plans to jointly build design tools, disease models, manufacturing processes, safety data, and clinical protocols covering precision gene therapies such as base editing and prime editing. Its central idea is not to turn every personalized medicine into a mass-produced product, but to enable different treatments to reuse some validated methods and evidence, making development more like a repeatable medical procedure.
The initial programs will focus on rare genetic epilepsies, developing precision gene-editing therapies for children, with up to $34.5 million in support from the THRIVE program of the U.S. Advanced Research Projects Agency for Health. This work is part of a broader commitment of up to $160 million to advance customized gene-editing approaches. However, “up to” denotes the maximum amount available; actual disbursements generally still depend on milestones and program progress and cannot be regarded as fully secured funding.
More difficult than the technology is how institutions can accommodate these drugs. Traditional drug review relies on clinical data from groups of patients to measure efficacy and risk statistically. When a treatment is intended for only one person or a handful of people, evidence cannot be generated at the original scale. The center says it will work with agencies including the U.S. Food and Drug Administration, the Department of Health and Human Services, and the Centers for Medicare & Medicaid Services to explore regulatory and reimbursement frameworks. Whether safety data can be reused across therapies, which manufacturing changes require renewed validation, and how public insurance should assess one-time, highly customized treatments all remain to be translated into workable rules.
The funding model likewise affects accessibility. If every family must raise funds on its own, access to treatment can easily depend on social resources and public exposure. The center aims to raise philanthropic support and prioritize cases that could not only help individual patients but also establish generalizable methods for subsequent programs. However, no public results are currently available to determine how cases will be selected, how much costs can be reduced, or whether this model can be sustained over the long term.
Background
Rare epilepsies have already been studied in single-patient trials using antisense oligonucleotides to target specific disease-causing gene copies, showing that even extremely small studies can accumulate clinical evidence through seizure frequency, functional changes, and continued follow-up. Gene editing goes a step further by altering DNA, potentially producing more durable effects while also making off-target changes, irreversible risks, and long-term monitoring more critical. The two types of therapies use different tools but face the same question: how to turn a one-off patient experience into knowledge that can be reused for the next patient.
For now, this initiative remains an infrastructure program, not a validated treatment platform. The center is still being established, has not yet begun providing clinical care, and does not accept patient referrals. Public information also provides no clinical timeline, human efficacy results, or complete safety data for the initial therapies. Whether it can transform rare-disease treatment will ultimately depend on whether shared data can genuinely shorten subsequent development and whether regulatory, manufacturing, and payment systems are willing to turn a small number of exceptional cases into a stable pathway.